<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069685/" ref="ordinalpos=1646&amp;ncbi_uid=2871839&amp;link_uid=PMC3069685" image-link="/pmc/articles/PMC3069685/figure/F2/" class="imagepopup">Figure 2. An essential ATF5-mediated survival <span class="highlight" style="background-color:">pathway</span> in malignant glioma.  From: An Activating Transcription Factor 5-Mediated Survival <span class="highlight" style="background-color:">Pathway</span> as a Target for Cancer Therapy. </a></div><br /><div class="p4l_captionBody">Cell surface receptors (FGFR or EGFR) activate RAS/MAPK or PI3K signaling pathways through FGFR substrate 2 (FRS2) and culminate in the activation of CREB3L2, which in turn stimulates transcription of ATF5. ATF5 then antagonizes apoptosis by directly up-regulating expression of the anti-apoptotic factor MCL1. Commercially available pharmacological inhibitors of several components of the ATF5-mediated survival pathway are indicated in gray.</div></div>